back to overview


How to pitch to a healthtech Investor

February 23, 2021 + Jessica Di Palo
3 Min read

What you need to know when pitching to a healthtech investor!

Healthtech investor pitching idea

Pitching a healthtech investor is not an easy exercise for many entrepreneurs because you may never get a second chance to make a good first impression!

When you are starting a presentation about your company, focus on setting the scene by describing the current environment with its related challenges and pain points. Then present the unmet medical need, which must be clearly identified in order to demonstrate how you are solving the issue and why your product is better than its competitors.

Entrepreneurs must be able to present the value their company is adding to stakeholders because healthcare is a value-based market where only ‘must-have’ solutions can survive and because insurance will never pay for ‘nice-to-have products’. The general constraint on healthcare spending continues to accentuate this fact.

The goal is to show that your solution has a competitive advantage and you are able to secure it with key assets such as (clinical) validation data, patents, a proprietary data set to train your machine learning or an existing customer network. These kinds of assets add a lot of value to your company because they de-risk the investment in the investor’s eyes.

A good value proposition with a sizeable cash amount is not equal to success without cornerstones demonstrating a feasible plan and the right capabilities to execute the vision. Your roadmap should include value inflection points, usually defined by target milestones, their related activities, and how the money raised is allocated over time.

This planning exercise is important and often underestimated by companies, but it provides clarity for an investor about the management’s view. The team must demonstrate technical knowledge and expertise, but also sales and marketing skills.

Exit scenarios need to be addressed with potential future buyers and timelines because most venture capital funds are closed-ended (normally 8-10 years lifespan), which means they need to be liquidated in a certain timeframe. Keep in mind that exit triggers the venture capitalist’s strategy!

The first interaction between an entrepreneur and an healthtech investor will start at two different sides of the table but might end up side by side, in the same boat. At the end of the journey, transparency, honesty, and open communication are essential for rowing faster together.

We wish you a lot of success when pitching to your next healthtech investor!

written by Dr. Christoph Kausch – Managing partner at MTIP.

Share the Article


SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right


MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round


MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia


Private Equity 101: Part one – Glossary

Are you new to the healthtech space?


Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey


Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations


MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II


How to pitch to a healthtech Investor

Blog Pitching


MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health


MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020


4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour


MTIP invests in Trialbee

New investment in Trialbee


TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round


The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April


MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020


New MTIP investment in Oviva

New investment in Oviva


Whitepaper: A positive prognosis for the future of healthtech

Our first Whitepaper


Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch

Elite Summit 2019


MTIP Healthcare Clinic 2019

Healthcare clinic 2019

New MTIP investment in Cynerio

New investment in Cynerio


MTIP invests in Lumeon Ltd.

New investment in Lumeon

Magenverkleinerung mit der Handnähmaschine

Nitinotes news paper article


New MTIP investment in Quanta Dialysis Technologies

New investment in Quanta